Abstract | Chaperone-mediated autophagy (CMA) was the first studied process that indicated that degradation of intracellular components by the lysosome can be selective -a concept that is now well accepted for other forms of autophagy. Lysosomes can degrade cellular cytosol in a nonspecific manner but can also discriminate what to target for degradation with the involvement of a degradation tag, a chaperone and a sophisticated mechanism to make the selected proteins cross the lysosomal membrane through a dedicated translocation complex. Recent studies modulating CMA activity in vivo using transgenic mouse models have demonstrated that selectivity confers on CMA the ability to participate in the regulation of multiple cellular functions. Timely degradation of specific cellular proteins by CMA modulates, for example, glucose and lipid metabolism, DNA repair, cellular reprograming and the cellular response to stress. These findings expand the physiological relevance of CMA beyond its originally identified role in protein quality control and reveal that CMA failure with age may aggravate diseases, such as ageing-associated neurodegeneration and cancer. or flies, that accelerated discovery in macroautophagy are of no use in the study of CMA as one of the essential CMA components is absent in these species and, to date, has been described only in birds and mammals 12 .
Last year, Yoshimori Ohsumi received the Nobel Prize in Medicine or Physiology for his molecular discoveries in autophagy. Work from many groups since the discovery of lysosomes has paved the way to our current understanding of the autophagic mechanisms that mediate the delivery of cytosolic proteins and organelles to lysosomes for degradation 1, 2 . These new findings have proved that autophagy can be very selective in what it targets for degradation (cargo) 3 , an idea that originally encountered considerable resistance.
It was during this early resistance that the discovery of chaperone-mediated autophagy (CMA) occurred. At that time, the best-characterized form of autophagy was macroautophagy, a process during which cargo that is sequestered in double-membrane vesicles (autophagosomes) is delivered to lysosomes through vesicular fusion 4 ( Fig. 1 ). This apparent in bulk trapping of cytoplasm inside autophagosomes was not compatible with the idea of selective degradation. A similar in bulk principle applied to microautophagy, whereby invaginations at the lysosomal membrane (or the vacuole in yeast) internalize cytosolic cargo into small vesicles that then detach into the lumen for degradation 5 ( Fig. 1 ).
Macroautophagy and microautophagy are now known to be capable of exquisite cargo selectivity. Macroautophagy uses cytosolic receptor proteins (for example, sequestosome 1 (p62)), next to BRCA1 gene 1 protein (NBR1) and NIP3-like protein X (NIX; also known as BNIP3L), that bring cargo and the autophagy machinery together 3 . This spatial coincidence allows assembly of the autophagy proteins to form a limiting membrane around the cargo. This membrane grows and seals, giving rise to an autophagosome with the cargo and receptors inside. Selective organelle degradation by microautophagy occurs by interaction of organelle proteins with surface proteins at the vacuole, lysosomes or late endosomes 6, 7 , whereas a cytosolic chaperone, the heat shock cognate 71 kDa protein (HSC70; also known as HSPA8), mediates selective protein degradation by microautophagy (known as endosomal microautophagy in mammals) 8 ( Fig. 1 ).
Selectivity has been associated with CMA since its discovery because of the unique mechanism that underlies lysosomal cargo delivery. Proteins, the only cargo degraded by this pathway, cross the lysosomal membrane one by one. Not all proteins can undergo degradation via CMA. To be CMA substrates, proteins must contain a specific targeting motif in their amino acid sequence 9 . This motif binds to a cytosolic chaperone (HSC70), which brings the substrate protein to the lysosomal surface for internalization and rapid intralysosomal degradation.
The focus of CMA studies has shifted through the years. Early studies optimized systems to reconstitute CMA in vitro, which helped in understanding chaperone-cargo recognition and substrate lysosomal translocation 10, 11 . Molecular dissection of CMA has been slow because model systems, such as yeast, worms
Chaperone
A protein that assists during folding of other proteins until they reach their functional conformations. Chaperone substrates include both de novo synthesized native proteins and previously folded proteins that undergo partial unfolding.
The coming of age of chaperone-mediated autophagy or flies, that accelerated discovery in macroautophagy are of no use in the study of CMA as one of the essential CMA components is absent in these species and, to date, has been described only in birds and mammals 12 .
The introduction of mammalian RNAi technology facilitated the identification of new components and regulators of the CMA pathway [13] [14] [15] [16] . The ability to genetically modulate CMA has been key, in recent years, to linking CMA malfunctioning to human diseases, such as neurodegeneration and cancer 17, 18 . Current studies on CMA at the cellular and organism level are providing a more comprehensive view of its physiological relevance by discovering previously unknown CMA functions [19] [20] [21] . For example, genetic blockage of CMA in mouse liver has revealed a key role for CMA in the regulation of glucose and lipid metabolism, whereas mouse models with compromised CMA in T cells support the requirement for a fully functional CMA to reach maximal T cell activation.
In this Review, we describe recent advances in our understanding of the mechanisms of CMA and the finely tuned orchestration of CMA activity as part of the proteostasis networks. We also discuss new findings on the pathophysiological relevance of CMA, particularly in the context of ageing and two age-related disorders (neurodegeneration and cancer).
Mechanisms of CMA
Biochemical and genetic approaches have helped dissect the steps and molecular machinery involved in CMA. These studies have confirmed the unique characteristics of CMA regarding substrate identification and delivery inside lysosomes when compared to other types of autophagy.
The basis for cargo selectivity
The concept of selective lysosomal degradation by CMA originated from the finding that not all cytosolic proteins could undergo lysosomal degradation. Using ribonuclease A, which is one of the proteins that can be degraded, the late American biochemist and cell biologist Fred Dice and his team identified an 11-amino-acid region in the protein, later narrowed down to the pentapeptide KFERQ, which is necessary and sufficient to target proteins for lysosomal degradation 22 . The properties of the residues that constitute the motif, rather than the specific amino acids, determine whether the CMA-targeting chaperone HSC70 can bind to this region 9 . The motif is always flanked by a glutamine on one of the sides (as the pentapeptide functions as a targeting sequence in both directions) and contains one or two of the positive residues K and R, one or two of the hydrophobic residues F, L, I or V and one of the negatively charged E or D residues. Approximately 40% of proteins in the shock protein 40 (HSP40; also known as DNABJ1) and HSP70-HSP90 organizing protein HOP modulate substrate targeting to lysosomes in an HSC70-dependent manner 32, 33 , to date, HSC70 remains the only chaperone proved to directly bind the KFERQ-like motif. HSC70 participates in multiple cellular functions by facilitating folding of unfolded or misfolded proteins. HSC70 binds hydrophobic regions to assist in protein folding. In contrast, HSC70 binds KFERQ-like motifs to target proteins for degradation via CMA.
The relationship of cytosolic HSC70 with autophagy has expanded beyond CMA. In cooperation with the cochaperones BAG family molecular chaperone regulator 1 (BAG1) and BAG3, HSC70 participates in the selective degradation of ubiquitin-positive protein aggregates by a type of macroautophagy known as chaperone-assisted selective autophagy (CASA) 34 ( Fig. 1) . The search for a process in mammalian cells that is homologous to yeast microautophagy led to the discovery of endosomal microautophagy, in which cytosolic proteins enter endosomal compartments inside vesicles generated at the surface of late endosomes through the assembly of endosomal sorting complexes required for transport (ESCRT) 8 . Although cytosolic proteins are trapped in a nonselective manner as these vesicles form, a subset of cytosolic proteins are selectively targeted there by HSC70 (REF.
8 ) (Fig. 1) . As in CMA, HSC70 binds endosomal microautophagy cargo proteins through a KFERQ-like motif. HSC70 is thus at the centre of protein triage between three different types of autophagy in mammals.
Discovery of selective endosomal microautophagy 8 has necessitated revising the criteria for bona fide CMA substrates. Dependence on HSC70 for lysosomal degradation, for many years a distinctive characteristic of
HIF1α
The hypoxia-inducible factor 1α is a transcription factor that modulates the cellular response to hypoxia. HiF1α orchestrates the transcription of a large set of genes involved in cell proliferation, cell survival, and glucose and iron metabolism.
E3 ubiquitin-protein ligase intracellular enzyme that participates in the covalent attachment of ubiquitin moieties to cargo proteins. This tagging is commonly used for the targeting of the protein to the proteasome system for degradation.
MST1
The mammalian STE20-like protein kinase 1 is a protein component of the Hippo signalling pathway that modulates cell proliferation and differentiation.
Cochaperones
Proteins that assist chaperones in their functions by modulating their ATP hydrolytic capability.
HSP90
Heat shock protein 90 is a chaperone that stabilizes proteins in transient conformations and facilitates their final folding. HSP90 often acts in conjunction with other intracellular chaperones such as HSC70.
mammal ian proteome contain a canonical KFERQ-like motif. In addition, in some substrate proteins, the same targeting motif can be generated through post-translational modi fications, thus expanding the number of potential CMA substrates. Phosphorylation of S, T or Y present in a motif containing only four of the canonical residues and missing the negatively charged one can complete the motif and convert the protein to a CMA substrate [23] [24] [25] [26] . In some instances, Q can be replaced by K, which upon acety lation acquires properties similar to Q, thus completing the motif 27, 28 . Ubiquitylation or acetylation of the same K could, in theory, become a switch between proteasomal and lysosomal degradation. Characteristics of canonical or putative CMA motifs and recommendations for motif validation are described in Box 1.
Post-translational modifications outside the motif can also modulate CMA targeting of proteins bearing canonical motifs by facilitating conformational changes that expose or mask the motif. For example, CMA-dependent degradation of hypoxia-inducible factor 1α (HiF1α), a validated CMA substrate, takes place only when it is ubiquitylated on Lys63 by the E3 ubiquitin-protein ligase STUB1 (REF.
29
). By contrast, acetylation of mammalian Ste20-like kinase 1 (MST1; also known as STK4) in a residue far from the canonical CMA motif prevents its lysosomal degradation, and only upon deacetylation can HSC70 bind the canonical motif 30 .
HSC70 involvement in CMA
The KFERQ-like motif provided the 'bait' to identify HSC70 as the cytosolic chaperone that, upon binding that region, targeted proteins for lysosomal degradation 31 . Although cochaperones, such as carboxyl terminus of HSC70-interacting protein (CHIP), heat
Box 1 | Validation of KFERQ-like motifs for CMA targeting
Despite the dynamic nature that post-translational modifications have conferred to the KFeRQ-like motif, it is important to notice that the specific requirements for a motif to function in chaperone-mediated autophagy (CmA) targeting have been established and validated experimentally. Several published studies have proposed as CmA-targeting motifs what appear to be randomly chosen sequences. In order to maintain consistency and avoid confusion in the field, it is important that any new proposed motif is validated experimentally according to the following original criteria: elimination of the motif abolishes lysosomal degradation of the protein independent of macroautophagy; insertion of the proposed motif in a well-characterized non-CmA substrate makes it amenable to CmA degradation; and elimination or mutation of residues in the motif suppresses binding of the protein to heat shock cognate 71 kDa protein (HSC70; also known as HSPA8), or if there is still HSC70 binding, it can no longer compete with a KFeRQ-containing peptide.
The figure summarizes the types of post-translational modifications to take into consideration as possible enablers or disruptors of HSC70 bind ing to substrate proteins through the KFeRQ-like motif (details in the main text). examples of canonical motifs and how post-translational modifications can complete a motif are shown in the left panel, whereas the right panel illustrates how post-translational modifications in a protein outside the motif can change the protein conformation and unmask the KFeRQ-like motif.
CMA substrates, is now insufficient to attribute degradation to this pathway. Dependence on the lysosomal membrane receptor lysosome-associated membrane protein type 2A (LAMP2A, discussed below), is the best criteria to determine whether protein degradation occurs via CMA, as LAMP2A is not required for CASA 34 or endosomal-microautophagy 8 . Whereas HSC70 requires LAMP2A for lysosomal docking in CMA, the chaperone binds directly to lipids at the endosomal membrane in endosomal microautophagy 8 . A fraction of cellular HSC70 that is constitutively present in lysosomes, both at their membrane cytosolic side and in the lysosomal lumen, also participates in CMA 15, 35 (Fig. 2) . Membrane-bound HSC70 in a complex with the cochaperones HSP90, HSP40, HSP70-interacting protein (HIP) and HOP has been proposed to participate in substrate unfolding 33 , which is required before lysosomal translocation 36 . Membrane HSC70 is also required to sustain continuous cycles of CMA because after the substrate is internalized, HSC70 facilitates dissociation of the receptor protein from the CMA translocation complex to allow for binding of new substrates 15 . The second form of lysosomal HSC70 is located in the lumen 35, 37 (Fig. 2) . The stability of HSC70 in this acidic environment with high concentrations of proteases relies on specific properties of the luminal HSC70. Although both cytosolic and lysosomal HSC70 originate from the same gene, it was shown that luminal HSC70 has a highly acidic isoelectric point, which is very different from the neutral isoelectric point of the cytosolic chaperone 37 . Luminal HSC70 becomes unstable with small changes in lysosomal acidification, which are physiologically used to modulate the percentage of lysosomes competent for CMA at a given time 35 . As luminal HSC70 is necessary to complete substrate translocation, lysosomes lacking this chaperone cannot perform CMA. An unresolved question is how HSC70 gains access to the lysosomal lumen. Blockage of macroautophagy or CMA does not reduce the levels of luminal HSC70 (REF. 13, 38 ), thus discarding the possibility that it might be internalized through these pathways. It is possible that HSC70 internalization from the cytosol occurs into late endosomes through microautophagy and that lysosome-endosome fusion facilitates HSC70 transfer to the lysosomal lumen.
Diverse functions of the lysosomal receptor LAMP2A
LAMP2A was the first identified lysosomal component required for CMA 39 . Participation of a receptor protein in CMA was inferred because substrate internalization in lysosomes was saturable and trypsinization of the surface of lysosomes (to remove protein components) ablated substrate binding and internalization 35, 40 . LAMP2A is one of the three splice variants of a single gene, LAMP2
.
LAMP2A, LAMP2B and LAMP2C have identical luminal regions but different transmembrane and cytosolic regions. LAMP2A is the only one of the three isoforms required for CMA 39, 41 (Fig. 2) . Although LAMP2A may share with LAMP2B and LAMP2C some of the functions attributed to the luminal region that is identical in the three LAMP2 variants 42 , it is not the most abundant of Lysosome-associated membrane protein (LAMP). Single-span membrane proteins at the lysosomal membrane with a short C-terminus (12 amino acids) exposed to the cytosol while the rest of the protein is in the lysosomal lumen.
Isoelectric point
The pH at which the net charge on a protein is zero.
the three proteins, and its blockage remains, to date, the most specific way to inhibit CMA. LAMP2A contributes to different steps of CMA.
Substrate binding. The 12-amino-acid cytosolic tail of LAMP2A is required for lysosomal docking of HSC70-substrate complexes 39, 41 . HSC70 and the substrate can bind this tail at the same time, suggesting that substrate recognition and targeting are coupled processes 39, 41, 43 ; however, the KFERQ-like motif in the substrate is not required for LAMP2A binding 39 . Three positive residues in the cytosolic tail of LAMP2A are essential to complete CMA of substrates 41 , leaving open the possibility that transferring of the unfolding substrate requires interaction only with negatively charged residues in the substrate protein. Studies using an unfoldable artificial substrate demonstrated that unfolding is not required for lysosomal surface binding but is necessary for its translocation 36 .
LAMP2A assembly. Multimerization of LAMP2A into a 700 kDa multimeric protein complex is essential for substrate translocation into the lumen 14, 15 ( Fig. 2) . Assembly of this translocation complex occurs step-wise and includes the formation of an intermediate LAMP2A homotrimer 44 that increases substrate affinity and probably prevents its aggregation as the substrate unfolds 44 . Cytosolic HSC70 associates with LAMP2A monomers and homotrimers, but it is released before the fully functional translocation complex is assembled 15 . A form of HSP90 associated at the luminal part of the lysosomal membrane interacts with and stabilizes LAMP2A during this transition 15 ( Fig. 2 ). HSP90 may cover protease-sensitive regions of LAMP2A that are otherwise exposed during its conformational arrangement for multimeric assembly 15 .
Regulation of lysosomal levels of LAMP2A. Luminal HSC70 is required for CMA, but LAMP2A is the rate-limiting component of this pathway. Changes in levels and dynamics of LAMP2A at the lysosomal membrane regulate CMA flux (that is, the rate at which cargo is degraded). De novo synthesis of LAMP2A occurs during mild oxidative stress 21, 45 , genotoxic damage 24 or hypoxia 32, 46 -all conditions that induce CMA activation. This transcriptional upregulation of LAMP2A is still poorly understood. The transcription factor nuclear factor of activated T cells (NFAT1) has been shown to directly promote the transcriptional upregulation of LAMP2A during T cell activation 21 ( Fig. 3) .
Transcription of several CMA components, including LAMP2A, have been shown to be under the negative control of the nuclear retinoic acid receptor-α
47
. Although most lysosomal proteins, including other LAMPs, are part of the programme of the transcription factor EB (TFEB), LAMP2 transcription is not regulated, at least directly, by this factor 48 . The increase in LAMP2A levels in other conditions that activate CMA, such as starvation, does not involve de novo synthesis of LAMP2A and is instead mediated through changes in LAMP2A degradation at the lysosomal membrane, which is a finely controlled In most cells, chaperone-mediated autophagy (CMA) participates in protein quality control by degrading oxidized and damaged proteins under stress conditions and also contributes amino acids through degradation of proteins at advanced times of starvation. In addition, depending on the protein substrate degraded, CMA has a modulatory role in multiple cellular pathways. This CMA-mediated selective remodelling of the proteome has recently demonstrated a role for CMA in modulation of carbohydrate and lipid metabolism, transcriptional programmes, immune responses and the cell cycle. The selective CMA substrates linked to those pathways are shown in blue boxes. GFAP, glial fibrillary acidic protein; HSC70, heat shock cognate 71 kDa protein; HSP90, heat shock protein 90; L AMP2A , lysosome-associated membrane protein type 2A ; lys-HSC70, lysosomal HSC70; TCA , tricarboxylic acid.
Nuclear retinoic acid receptor-α
Nuclear receptor activated by retinoic acid that activates or represses gene expression. its wide range of targets include genes involved in development, apoptosis, differentiation, autophagy and circadian regulation.
process 43, 49 (Fig. 2) . LAMP2A is usually well protected from the luminal proteases by its abundant glycosylation and unique spread conformation against the inner leaflet of the membrane 50 . Degradation of LAMP2A requires its mobilization to lipid microdomains 49, 51 , where it undergoes a dual cleavage by cathepsin A and a yet unidentified metalloproteinase to be released into the lumen for rapid degradation 51 ( Fig. 2) . Changes in the lipid composition of the lysosomal membrane with age or upon high-lipid dietary challenges accelerate this regulated degradation of LAMP2A because it becomes trapped in the expanded lipid microdomains 52, 53 . The half-life of LAMP2A in lyso somes is approximately 36 h, but it becomes more than 72 h in hepatocytes and in fibroblasts in culture during prolonged starvation 51 . This reduced degradation leads to a net increase in LAMP2A levels in lysosomes. Mobilization of a fraction of LAMP2A resident in the lysosomal lumen (likely in micelles) to the lysosomal membrane is responsible for the further increase in LAMP2A levels at the lysosomal membrane observed when starvation persists beyond 48 h (REF.
43
).
There is no evidence yet that Golgi complex-tolysosome trafficking of LAMP2A modulates CMA activity under physiological conditions. However, mistargeting of LAMP2A has been identified as the basis of reduced CMA observed in the lysosomal storage disorder cystinosis 54 . Defective trafficking seems specific for LAMP2A, as other LAMPs reach lysosomes normally in this disease, thus suggesting the existence of LAMP2A-dedicated Golgi-to-lysosomal transport machinery. The small GTPase Ras-related protein Rab-11A (RAB11) and the RAB7 effector Rab-interacting lysosomal protein (RILP) are likely part of this transport machinery, as correction of the lower levels observed for both proteins in patients is sufficient to correct LAMP2A mistargeting in disease cells 55 . Small molecules that activate CMA by releasing the inhibitory effect of retinoic acid receptor-α (RARα) on several CMA components 47 also correct LAMP2A trafficking 55 . Altered endosome-to-Golgi retrieval of LAMPs has been found in cells bearing mutations in the retromer component vacuolar protein sorting-associated protein 35 (VPS35). These mutations have been identified in patients with Parkinson disease (PD) 56 , which was the first neurodegenerative disorder associated with defective CMA activity 17 . However, contrary to the selectivity for LAMP2A observed in cystinosis, VPS35 mutations alter trafficking of multiple lysosomal proteins, suggesting a more general lysosomal malfunction in these conditions 56 .
Dynamics of LAMP2A assembly. Changes in rates of LAMP2A assembly and disassembly from the translocation complex impact overall CMA activity (Fig. 2) . A pair of proteins, the monomeric form of the intermediate filament protein glial fibrillary acidic protein (GFAP) and its GTP-binding partner elongation factor 1-α (EF1α) modulate the stability of multimeric LAMP2A in a GTP-dependent manner 14 . Part of GFAP at the lysosomal membrane is phosphorylated and bound to EF1α, and part is unmodified and bound to the LAMP2A multimeric complex, conferring stability 14 . In the presence of GTP, EF1α dissociates from phospho-GFAP, thus promoting mobilization of GFAP from the translocation complex to phospho-GFAP and the subsequent disassembly of LAMP2A 14 .
Conditions that change the lipid composition of the lysosomal membrane impact CMA. High-lipid-content diets change the lysosomal membrane lipidome, which compromises both LAMP2A stability and its ability to multimerize 52 . Interestingly, changes in the lysosomal membrane lipidome with age have comparable effects on LAMP2A stability and dynamics 52 . It is plausible that interventions to modify lipid membrane composition could be utilized to modulate CMA activity under pathological conditions. Physiological regulation of CMA CMA was initially described as part of the cellular response to stress, but basal CMA activity is detectable in almost all mammalian cells 57 . The tools and assays currently available to study CMA are summarized in TABLES 1,2. Basal levels of CMA differ widely among cell types and tissues, suggesting possible differences in their dependence on CMA. CMA is upregulated in response to a large variety of stressors, such as starvation, oxidative stress, genotoxic insults, lipid challenges, hypoxia and radiation 24, 29, 40, 45, 58, 59 . Integration of CMA with the rest of the cellular stress response requires fine-tuning of CMA activity. Although much is yet to be discovered about physiological regulators of CMA, cues from cytosolic signalling pathways and signalling events at the lysosomal membrane have been shown to regulate CMA (Fig. 2) .
NFAT and calcium signalling
The first signalling pathway identified in the activation of CMA was the calcineurin-NFAT pathway, required for CMA activation in T cells 21 , which also provided novel insights on CMA activation in response to oxidative stress 45 . The transcription factor NFAT1 directly binds the lamp2 proximal promoter region, which contains several putative NFAT1-binding sites. Generation of reactive oxygen species (ROS) during T cell activation promotes the nuclear translocation of NFAT1 and the subsequent increase in lamp2a expression. Both calcineurin inhibition by cyclosporine A or blocking ROS production ablate CMA activation in these cells 21 . T cell receptor (TCR)-induced CMA activation favours CMA degradation of TCR signalling inhibitors such as E3 ubiquitin-protein ligase Itchy homolog (ITCH) and regulator of calcineurin 1 (RCAN1) -a requirement for maintaining T cell activation in these cells 21 .
RARα signaling
Signalling through RARα, but not through other abundant members of this nuclear receptor family (such as RARβ, RARγ or RXR), inhibits CMA 47 . Genetic and chemical blockage of RARα demonstrate that not only LAMP2A 47 but also proteins that facilitate LAMP2A trafficking to lysosomes, such as RAB11 or RILP, are also under the negative regulation of this receptor 55 . It is thus likely that RARα controls a discrete CMA-related transcriptional programme. In fact, structure-based
Lipid microdomains
Cholesterol and/or glycosphingolipid-rich regions in membranes that present higher order and density than the surrounding membrane. They can be transient and highly dynamic in terms of resident proteins and lipids and in their size.
Cathepsin
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Cystinosis
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chemical design has made possible generating synthetic derivatives of all-trans retinoic acid that block only the inhibitory effect of RARα on CMA without affecting the RARα-dependent transcriptional programme 47 . Chemical upregulation of CMA with these compounds rendered cellular protection from oxidative stress and proteotoxicity 47 . Given the ubiquitous expression of RARα, these atypical RARα inhibitors hold great promise in the systemic restoration of impaired CMA in ageing.
The TORC2-AKT1-PHLPP1 axis Physiological regulation of CMA activity also occurs directly at the lysosomal membrane. As previously mentioned, dynamics of the CMA translocation complex depend on GFAP phosphorylation status 14 , which determines its oligomeric state. Lysosomal GFAP phosphorylation is performed by a form of AKT1 that resides at the lysosomal membrane 16 . AKT1 activity is closely monitored by the phosphatase PH domain leucine-rich repeat-containing protein phosphatase 1 (PHLPP1) and the kinase ToR complex 2 (TORC2) 16 at the lysosomal membrane (Fig. 2) . Lysosomal TORC2 phosphorylates AKT1, which, by phosphorylating GFAP, puts a break on CMA activity. Contrary to TORC1, TORC2 does not shuttle and is always present at the membrane of CMA-active lysosomes 16 . TORC2 and AKT1 exert sustained inhibition on CMA as chemical TORC2 inhibitors such as torin (at concentrations that do not affect TORC1), knockdown of the TORC2 component rapamycin-insensitive companion of mTOR (RICTOR), or chemical or genetic blockage of AKT1 all lead to CMA induction 16 . The TORC2-AKT1-axis inhibition on CMA is physiologically released through RAC1-dependent recruitment of the phosphatase PHLPP1 to the lysosomal membrane whenever CMA activation is needed 16 . PHLPP1 dephosphorylates AKT1, and inactivation of this kinase makes dephosphorylated GFAP available to accelerate the rounds of LAMP2A assembly and disassembly 16 ( Fig. 2) . Confining these signalling events to the lysosomal membrane may allow fine-tuning of CMA to rapidly adjust to the cellular needs. Interestingly, several of the CMA regulators at the lysosomal membrane (that is, GFAP, EF1α, RICTOR and AKT1) contain CMA-targeting motifs and undergo some, albeit discrete, lysosomal degradation 14, 16 . It is tempting to speculate that the targeting motif may be used not only for degradation but, in some instances, for delivery of CMA regulators to the lysosomal membrane and that degradation of these regulators by CMA may be a way to terminate their stimulatory or inhibitory effect on CMA.
Physiological roles of CMA The diverse nature of already identified CMA substrates and the additional potential CMA substrates that can be generated by post-translational modification justifies the variety of cellular processes impacted by CMA (Fig. 3) . Early studies emphasized the role of CMA in protein quality control and considered abnormally synthesized or post-translationally damaged KFERQ-containing proteins as main CMA substrates 45 . However, the finding that during starvation most KFERQ-bearing proteins can undergo CMA degradation revealed that protein damage is not a requirement for CMA targeting. There is evidence that properly folded, fully functional proteins can become CMA substrates in specific cellular scenarios and that their timely selective degradation by CMA contributes to the regulation of the cellular pathways CMA and protein quality control CMA activation is often triggered by stressors that cause protein damage, such as mild oxidative stress 45 , hypoxic stress 32, 58 or protein denaturation 60 , and in fact, CMA-incompetent cells and organs accumulate oxidized and aggregated proteins 13, 20 (Fig. 3) . CMA cannot degrade proteins once they aggregate, but it is part of the first line of defence against protein aggregation by mediating degradation of single proteins upon damage or partial unfolding 17, 61 . Interestingly, in tissues such as the liver, loss of proteostasis is not imminent upon CMA blockage because compensatory upregulation of macroautophagy and the proteasome can handle the load of CMA substrates 19 . However, ageing or additional stressors (that is, oxidative stress or lipid challenge) increase protein damage and aggregation in CMA-incompetent tissues, where the compensatory systems become insufficient to maintain proteostasis 20 . In further support of the role for CMA in protein quality control, both genetic and chemical upregulation of CMA in vitro and in vivo reduce levels of oxidized and aggregated proteins and improve cellular resistance against proteotoxicity 47, 62 .
CMA in the response to starvation
Lack of nutrients activates CMA in most organs and cell types tested 22, 40, 59 . Considering the role of autophagy in adaptation to starvation and the timing of CMA activation -after at least 8 h of starvation 13, 63 , when macroautophagy has already peaked -it was suggested that starvation-induced CMA provides cells with free amino acids for the generation of energy and for the synthesis of crucial proteins required for cell function (Fig. 3) . In organs such as the liver, proteolysis through macroautophagy lasts for about 8 h of starvation and then switches to preferential degradation of lipids 64 . In the face of nutrient deprivation beyond 10 h, the pool of intracellular amino acids may be mostly replenished through CMA, which is upregulated and sustained at this high level for up to three days in rodents 40 . CMA generates amino acids that sustain protein synthesis but some amino acids, such as alanine and glutamine, also provide the carbon skeletons for gluconeogenesis. Interestingly, tissues with high gluconeogenesis rates, such as the liver and kidney, are very active for CMA. In support of the contribution of CMA to cellular energetics, in vitro and in vivo models with impaired CMA exhibit reduced levels of ATP during nutrient deprivation 13, 18, 19 , while genetic restoration of CMA in aged mice normalizes their ATP levels 62 . The ability of CMA to generate free amino acids through degradation has been proposed to be utilized by pathogens, such as Salmonella, which recruits CMA components to gain host-derived peptides for its growth 65 . The signals that activate CMA during starvation are still for the most part unknown. Ketone bodies, the choice fuel in prolonged starvation, activate CMA 59 , and hydrolysis of amino acids derived from CMA generate α-ketoacids themselves, thus establishing a positive feedback loop between CMA and energy production. Intriguingly, CMA activation by ketone bodies occurs through generation of ROS 59 , suggesting that similar mechanisms to those described during T cell activation are in play.
An interesting combination of CMA-dependent quality control and cellular energetics has been recently described to occur through the CMA degradation of oxidatively damaged nonfunctional mitochondrial enzyme protein/nucleic acid deglycase DJ-1 (PARK7) 66 . By efficiently degrading this mitochondrial protein, CMA helps preserve mitochondrial function and should have a positive impact on cellular energetics 66 . Recent studies in mice with CMA-incompetent livers have revealed a new level of complexity in the interplay between CMA and cellular energetics whereby, 
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as described in the next section, CMA regulates the rates of metabolic pathways through timely selective degradation of key enzymes in these pathways 19, 67 .
Selective proteome remodelling by CMA
Protein degradation is extensively utilized by cells to downregulate cellular processes in which these proteins participate. The selectivity of CMA makes it suitable for this type of regulatory degradation, which underlies the basis of some of the recent novel physiological functions attributed to CMA (Fig. 3) Regulation of metabolic pathways. CMA contributes to the regulation of glucose and lipid metabolism through selective degradation of key enzymes in these pathways (Fig. 3) . Studies in mice have revealed that basal degradation of many metabolic enzymes via CMA in the liver is accelerated several-fold during fasting 19, 40 . Timely CMA degradation of glycolytic enzymes contributes, for example, to shutting off hepatic glycolysis during starvation, and failure to do so leads to abnormally elevated rates of hepatic glycolysis and the subsequent energy deficiency in peripheral organs 19 . Comparative proteomic analysis of lysosomes from CMA-defective mouse livers and from control littermates confirmed that the majority of the glycolytic enzymes and some of the enzymes in the tricarboxylic acid cycle undergo CMA degradation during starvation 19 . Abnormal upregulation of CMA activity, such as that observed in patients with tripeptidyl peptidase II (TPPII) mutations 68 can also become deleterious for cellular energetics. In this case, CMA activation is secondary to the lysosomal expansion that occurs upon the loss of TPPII in an attempt to maintain the pool of free amino acids normally provided by this peptidase. The caveat, however, is that general lysosomal upregulation increases degradation via CMA of hexokinase 2, a key glycolytic enzyme, which further impairs cellular energetics in these patients 68 .
CMA also contributes to regulate lipid metabolism (Fig. 3) . Proteins involved in lipid metabolismlipogenesis enzymes, lipid carriers and lipid droplet coat proteins -have been identified as bona fide CMA substrates 19, 67 . Control of both lipogenesis and lipolysis by CMA underlies the basis of the marked derangements in lipid usage and pronounced hepatosteatosis observed in CMA-incompetent mouse liver 19 . CMA facilitates lipolysis by selective degradation of lipid droplet coat proteins, such as perilipins 2 and 3 (PLIN2 and PLIN3) 67 . Selective removal of these proteins from the surface of the lipid droplets by CMA is required to facilitate access of cytosolic lipolytic enzymes and the macroautophagy machinery to the lipids stored in the core of the droplets to initiate both lipolysis and lipophagy 67 . These findings place CMA upstream of both lipolytic pathways. Timely removal of lipid droplet coat proteins by CMA during starvation is triggered in part via 5'-AMP-activated protein kinase (AMPK)-dependent phosphorylation of PLIN2 (REF.
23
). CMA contributes to keeping intracellular lipid levels in check by reducing lipogenesis and increasing lipolysis 19 . In fact, cells upregulate CMA in response to acute lipid challenges, and failure to do so results in cellular toxicity 52 .
Transcriptional regulation by CMA. Additional regulatory roles for CMA, beyond the control of metabolic pathways, have been recently identified (Fig. 3) . CMA regulates transcriptional programmes mediated by nuclear factor-κB (NF-κB) by degrading its inhibitor NF-κ-B inhibitor-α (IκBα) during starvation 69 . Timely CMA degradation of paired-box protein PAX2, a transcription factor important for cell proliferation and differentiation 70 , maintains renal size and growth, whereas CMA protects neurons against stressors through selective degradation of the transcription factors myocyte-specific enhancer factor 2A (MEF2A) and MEF2D, which are required for neuronal survival 71, 72 .
CMA and the immune response. CMA is important for CD4 + T cell activation because it selectively degrades two negative regulators of TCR signalling, namely, ITCH and RCAN1 (REF.
21 ) (Fig. 3) . Persistent high levels of these two factors in CMA-incompetent T cells are responsible for their reduced cell proliferation and cytokine secretion following activation. These observations unveil an important link between CMA activity and the immune response, further supported by the fact that mice with defective T cell CMA are compromised in their responses to immunization and to infection by pathogens such as Listeria monocytogenes 21 . Recent studies have revealed contribution of CMA to the regulation of innate immunity through degradation of stimulator of interferon genes protein (STING), a signalling protein in the response against cytosolic nucleic acids 73 . The trigger for STING degradation is desumoylation, which unmasks its KFERQ-like motif during the late phase of viral infection to shut off the innate immune response 73 .
Control of cell cycle. Following genotoxic insults, CMA is required to initiate cell cycle progression after DNA repair has been completed 24 . This effect is mediated in part by degrada tion of phosphorylated serine/ threonine-protein kinase CHK1 (also known as cell cycle checkpoint kinase), which in the absence of CMA, stays in the nucleus, interfering with DNA repair 24 ( Fig. 3) . CMA also degrades HIF1α 32, 46 , another regulator of cell cycle progression, thus adjusting its levels to the different phases of the cell cycle under conditions of hypoxia. This close regulation is possible through the opposite effects of a pair of cyclin-dependent kinases, whereby CDK1 blocks HIF1α lysosomal degradation, and CDK2 promotes it 46 . K63 ubiquitylation appears to be the trigger for degradation of HIF1α via CMA 29 .
Anti-ageing functions of CMA Age-dependent decrease in CMA activity occurs in almost all cell types and tissues in rodents and in humans 21, 22, 62, 74, 75 . Lower stability and therefore reduced levels of LAMP2A at the lysosomal membrane is one of the main causes of decline in CMA activity 53 . Changes in the lipid composition of the lysosomal membrane with age are responsible for the loss of LAMP2A stability 49, 52, 53 . Recently generated, tissue-specific AMP2A-knockout mice 19 have begun to expand our understanding of the organism's reaction to CMA
Perilipins
Proteins that cover the surface of lipid droplets and shield the hydrophobic lipid core from the aqueous cytosol. Perilipins also regulate the rate of consumption of the lipids (lipolysis) in the lipid droplet.
malfunctioning and the consequences of reduced function of this pathway with age. Studies in cultured cells have previously demonstrated crosstalk between macroautophagy and CMA, whereby cells respond to blockage of one of these pathways by upregulating the other 13, 38 . Similar positive compensation by macroautophagy has also been found in vivo in mouse models with selective blockage of CMA in liver or in T cells 19, 21 . However, studies in mouse retina suggest that compensation for CMA failure is not universal 75 . While the age-related decline in retinal macroautophagy coincides with pronounced upregulation of CMA, blockage of CMA does not elicit a compensatory activation of macroautophagy in this organ 75 , thus explaining its higher sensitivity to stress upon CMA blockage 75 . In general, although macroautophagy and CMA can compensate for some of each other's functions, they are not redundant, and their loss of function, even when the other pathway is upregulated, becomes evident. For example, CMA-incompetent livers do not accumulate damaged or aggregated proteins because increases in macroautophagy and the proteasome take over some of the CMA protein quality control functions. However, owing to the different timing of activation and substrate-targeting mechanisms of these two pathways, they cannot compensate for CMA regulatory functions and problems with metabolic flux, DNA repair, and so on, which become evident in these animal livers 19 . Furthermore, upregulation of macroautophagy and the proteasome in CMA-incompetent livers is rapidly lost when animals are subjected to stressors (that is, oxidative stress and lipid challenges) and as the animals age 20 . Compensation failure with age can explain the gradual loss of protein homeostasis and higher sensitivity to stress of aged AMP2A-knockout mice livers.
Genetic interventions to restore CMA function in old mouse liver have shown remarkable improvement in age-related changes in this organ. Expressing an inducible exogenous copy of Lamp2a protected aged livers from stressors and led to overall improvement in proteostasis and organ function 62 . Preventing the systemic decline of CMA with age may prove an attractive strategy against organism functional loss and age-associated disorders.
The contribution of CMA failure to human disease A better understanding of CMA dynamics, the identification of novel CMA molecular effectors and regulators and the development of tools to track CMA (TABLES 1, 2) have all contributed to linking CMA malfunctioning to a growing number of human diseases. We have selected two types of pathologies with defective CMA to illustrate examples in which diminished or increased CMA activity contributes to disease progression. A more comprehensive description of other CMA-related diseases, summarized in TABLE 3, can be found in recent reviews 76, 77 .
CMA failure in neurodegenerative disorders
The first connection between CMA malfunctioning and a human disease was with PD 17 . Since then, CMA failure has been linked to the pathogenesis of a growing number of neurodegenerative disorders (TABLE 3) . CMA contributes to the degradation of several proteins that have a propensity to aggregate and, consequently, a decline in CMA activity leads to the accumulation of toxic aggregates.
The pathogenic variants of several CMA substrates are involved in PD, Alzheimer disease, frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Neurodegeneration-related proteins validated as CMA substrates include α-synuclein 17, 61, [78] [79] [80] , PARK7 (REF. 66 ), leucine-rich repeat serine/threonine-protein kinase 2 (LRRK2) 81 and ubiquitin carboxyl-terminal hydrolase isozyme L1 (UCHL1) 82, 83 (in PD), Tau protein 84 , TAR DNA-binding protein 43 (TDP-43) 85 (in tauopathies such as Alzheimer disease or frontotemporal dementia) and huntingtin [86] [87] [88] (in Huntington disease). However, it is possible that a larger number of proteins that are associated with neurodegeneration are CMA substrates, as many other proteins in these diseases contain the KFERQ-targeting motif.
A common characteristic of these neurodegenerationrelated proteins is that, in most cases, the unmodified protein behaves as a conventional CMA substrate, whereas the pathogenic variants are targeted to lysosomes but fail to degrade and inhibit CMA (Fig. 4) . In PD, pathogenic forms of α-synuclein 17, 61, 89 , UCHL1 (REFS 82, 83 ) and LRRK2 (REF.
81
) bind cytosolic HSC70 but, unlike their wild-type counterparts, interact abnormally with CMA components at the lysosomal membrane. Their obliterated entry into the lysosomal lumen often favours their organization into oligomeric complexes at the lysosomal surface, which negatively impacts CMA-mediated degradation of other substrates and further disrupts neuronal proteostasis 17, 61, 78, 80, 82, 85, 90 . Failed assembly of LAMP2A into the CMA translocation complex upon binding of PD proteins to this receptor has been demonstrated as the basis of their toxic effect on CMA 81 . Accordingly, in vitro and in vivo upregulation of CMA with small molecules 47 or by viral-mediated LAMP2A expression 91 has been shown to decrease α-synuclein levels and to protect against neurodegeneration 91 . Similarly, Nrf2 (also known as Nfe2l2) expression in astrocytes slows down CMA decline in PD mice by as-yet unidentified mechanisms and has a similar neuroprotective effect 92 . CMA malfunction is becoming a common feature of most PD types, although CMA failure may originate through different mechanisms. Besides the direct toxic effect on CMA described for pathogenic α-synuclein, UCHL1 or LRRK2, PD-related proteins, such as mutant VPS35 (REF.
56
) or GBA1 (REF.
93
), may reduce CMA activity by affecting lysosomal biogenesis. Although direct measurement of CMA in PD patient brains is still not feasible, correlative evidence supporting CMA malfunctioning in PD patients has populated the literature in recent years (TABLE 3) . Reduced LAMP2A levels have been reported in both familial and idiopathic PD patients' brains 94 , especially in the areas more vulnerable to disease 95 . PD-linked sequence variants in the LAMP2 promoter 96 and increased levels of specific microRNA in PD patients 97 seem responsible, at least in part, for the changes in LAMP2A in PD brains. Early stage PD brains show reduced LAMP2A levels, even before α-synuclein accumulation, suggesting that CMA dysfunction is an early event in PD pathogenesis 95 . Several of the proteins associated with frontotemporal dementias and tauopathies, including Alzheimer disease, have also been validated as bona fide CMA substrates whose degradation through this pathway is reduced in the diseased brains 84, 85, 98, 99 . Similar to PD-related proteins, mutant forms of tau protein are targeted to lysosomes but fail to reach the lysosomal lumen 84 . In this case, the mutant proteins do not disrupt LAMP2A multimerization, but their translocation through this complex is halted halfway into the lysosomal lumen 84 (Fig. 4) . Incomplete translocation of mutant tau leads to its partial cleavage into highly amyloidogenic peptides that form irreversible oligomers at the lysosomal membrane, thus inhibiting CMA 84 . CMA also contributes to the degradation of other neurodegeneration-related proteins such as RCAN1 99 , ubiquilin 1 (REF.
100
) and TDP-43 (REF.
85
), but less information is available about the CMA of their pathogenic variants or their impact on CMA. An unexpected relation has been suggested between CMA and the processing of amyloid precursor protein (APP), a protein closely associated with Alzheimer disease 98 . APP is a single-span membrane protein and, as such, is not a candidate for CMA degradation. However, APP undergoes physiological cleavage to release a short cytosolic stub where, coincidentally, the KFERQ motif is located. Although direct evidence for its CMA degradation is still missing, mutation of this motif led to cytosolic accumulation of this small, highly toxic peptide 98 . Despite most studies pointing towards faulty functioning of CMA in neurodegenerative disorders, in Huntington disease, CMA activity is upregulated as a compensatory response to macroautophagy failure 87 . In fact, CMA can degrade both wild-type and mutant huntingtin, the protein that aggregates in the affected neurons, and artificial CMA targeting of mutant huntingtin has proved effective in reducing neurotoxicity in experimental mouse models 86, 88 . However, the therapeutic applicability of mutant huntingtin re-routing towards CMA may be limited by the fact that the normal age-related decline in CMA activity is accelerated in the Huntington disease brain 87 . Associations between CMA and other neuropathogenic proteins, such as prion proteins, and changes in CMA components in conditions, such as brain ischaemia or traumatic brain and spinal cord injury, have begun to appear (TABLE 3) .
Accumulating evidence points towards a failure in CMA in several neurodegenerative diseases. A common theme that has also emerged is that the mechanism of this CMA inhibition varies on a case-by-case basis. Studying the pathological protein along with the wild-type version and delineating the exact step affected in CMA would be key in providing specific therapeutic interventions.
Complex role of CMA in cancer biology
Despite connections between CMA and cancer having been first established little more than 6 years ago 18 , some common key features of this interplay have since emerged. CMA activity is markedly upregulated in most cancer cell lines, and levels of CMA components, mainly LAMP2A, are elevated in a large array of human tumours 18, 30, 101 (TABLE 3) . Blocking CMA in cancer cells adversely affects cell survival and decreases their tumorigenicity, whereas blocking CMA in preformed xenografts causes tumour shrinkage and reduces metastasis 18 . The bases for the pro-oncogenic effect of CMA are probably multiple and depend on the type and stage of cancer (Fig. 4) . The contribution of CMA to protein quality control explains why upregulating CMA provides the cancer cells several survival benefits, for example, resistance to hypoxia, oxidative stress and DNA damage -all key elements of a growing tumour microenvironment and of most anti-oncogenic interventions 26, [101] [102] [103] [104] [105] [106] [107] [108] . The role of CMA in tumour growth goes beyond quality control of damaged proteins and has been linked to selective degradation of specific regulatory proteins. Thus, CMA activity is required in some cancers to sustain the Warburg effect -aerobic glycolysis important for tumour progression 18, 27 . CMA degradation of some glycolytic enzymes, such as acetylated pyruvate kinase PKM2, results in increased levels of glycolytic intermediates, which promote growth and proliferation 27 . Additionally, CMA indirectly reduces p53 levels, thus releasing its transcriptional inhibition on key glycolytic enzymes and resulting in higher glycolytic rates 18 . CMA also sustains tumour growth by degrading antiproliferation proteins (such as Rho-related GTP-binding protein RhoE (RND3) 26 ), tumour suppressor proteins (such as Unique metabolic characteristic of many cancer cells whereby they sustain very high levels of glycolysis followed by lactic acid fermentation rather than the common usage of oxidation of pyruvate in mitochondria that follows glycolysis in most cells.
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), 15 kDa phosphoprotein enriched in astrocytes (PEA-15; also known as PED) 25 and mutant p53
(REF.
109
)) or pro-apoptotic proteins (such as Bcl-2-binding component 3 (BBC3; also known as PUMA 110 )), and by indirectly contributing to stabilize prosurvival proteins such as the induced myeloid leukaemia cell differentiation protein MCL1 (REF. 111 ). Accordingly, blockage of CMA in cancer cells causes oxidative stress and higher susceptibility to chemotherapeutic agents and apoptosis 101 , and is being pursued as a possible antitumorigenic intervention. Upregulation of CMA -beyond that already occurring in the tumour -after blocking macroautophagy and the proteasome promotes cell death in specific tumours through metabolic collapse due to rapid degradation of glycolytic enzymes via CMA 112, 113 . Despite this protumorigenic role of CMA in cancer cells, it is important to note that the role of CMA in non-transformed cells is remarkably the opposite and that all evidence supports an anti-oncogenic role for CMA under physiological conditions (Fig. 4) . CMA plays a tumour suppressive role in nontumorigenic cells by accelerating MYC's proteasomal degradation and thus abolishing its oncogenic activity 114 by directly degrading oncoproteins such as E3 ubiquitin-protein ligase MDM2 (REF. 115 ), and by perhaps facilitating immunogenic cell death
116
. CMA may also protect against malignant transformation by assuring genome stability through its role in efficient DNA repair 24 . Progressive decrease in CMA with age may thus contribute to the higher risk of malignant transformation in ageing. In fact, mice with hepatic blockage of CMA develop spontaneous tumours 20 . Therefore, interventions aiming to preserve or restore CMA activity in ageing individuals may have potential value in cancer prevention.
Conclusions and perspectives
Research on CMA has a long way to go to reach the wealth of knowledge accumulated on other forms of autophagy during the past 2 decades. However, the identification of the essential CMA molecular players, the better understanding of the unique dynamics of CMA substrate degradation and the in vivo validation of the physiological relevance of CMA through the study of transgenic mouse models have all contributed to the coming of age of CMA. Discovery of the regulated LAMP2A multimerization at the lysosomal membrane was key in understanding how CMA is regulated at the mechanistic level, but in the cellular context, the number of signalling pathways known in CMA regulation is still discrete, especially when considering the variety of CMA-activating stimuli present. Whether endosomal microautophagy is the CMA alternative in species where LAMP2A is not present or whether there could be yet another CMA-equivalent pathway in these species needs exploration. The growing evidence in support of a close interplay between CMA and macroautophagy makes it a priority to understand the molecular players involved in this crosstalk. Ongoing studies using high-resolution technologies on CMA reconstituted translocation units should provide new insights on the energetic requirements, driving forces and roles of cochaperones and chaperones at each side of the lysosomal membrane. Chaperone-mediated autophagy (CMA) malfunctioning has been observed in multiple human disorders. Depicted here are two conditions, neurodegeneration and cancer, for which stronger experimental evidence of CMA involvement has been obtained. In neurodegeneration, pathogenic proteins can exert a toxic effect on CMA directly by disrupting the dynamics of the CMA translocation systems or indirectly by affecting levels of CMA effectors or lysosomal biogenesis. Most studies support that CMA has an anti-oncogenic role in normal untransformed cells and prevents malignant transformation, at least in part, through the mechanisms depicted here. In contrast, CMA has a protumorigenic effect in cancer cells by favouring their replication and growth and protecting them from extracellular insults. GFAP, glial fibrillary acidic protein; HSC70, heat shock cognate 71 kDa protein (also known as HSPA8); HSP90, heat shock protein 90; L AMP2A , lysosome-associated membrane protein type 2A ; lys-HSC70, lysosomal HSC70.
Immunogenic cell death
Functionally peculiar variant of regulated cell death that -in immunocompetent syngeneic hosts -is sufficient to activate an adaptive immune response against dead cell-associated antigens.
CMA bears functions common to all cell types (that is, protein quality control) and also more cell-typespecific regulatory functions that stem from its ability to selectively degrade single still-functional proteins. The introduction of mouse models with increased or reduced CMA and the future expansion of the tissue-specific conditional models will help us better understand these CMA regulatory functions and how tissue-specific changes in CMA impact whole organism function. Similarly, despite the already impressive list of connections between CMA malfunctioning and disease, a large number of them are still correlative, and experimental evidence of changes in CMA activity, the CMA step affected and the molecular mechanisms by which CMA contributes to pathogenesis is still missing. Is the toxic effect of α-synuclein or tau protein on CMA reversible? What are the more vulnerable CMA steps and/or components? Is CMA upregulation in these disease conditions always possible, or is there a 'point of no return'? Multiple questions also surround the dual role of CMA as an anti-oncogenic mechanism in normal cells but a protumorigenic one in transformed cells. What mediates the switch from low to high CMA during transformation? How do oncogenic proteins protect themselves from CMA degradation in the cancer cell? As our knowledge of the contribution of CMA malfunction to disease grows, the need for good chemical modulators of CMA will increase. Despite recent success in the development of selective CMA activators 47 , the field still lacks selective inhibitors of CMA beyond those that inhibit lysosomal proteolysis and thus disrupt all forms of autophagy. Research on CMA has reached a mature stage, and the recent advances in understanding its cellular functions and uncovering new links between CMA failure and human diseases open new avenues for basic and clinical research.
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